{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:07:11Z","timestamp":1780582031650,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Sex influences chemotherapy-induced nausea and vomiting (CINV). However, in clinical practice, males and females receive the same antiemetic prophylaxis. We compared CINV between sexes in patients with different emetic risk schemes and evaluated the predisposing factors and main adverse effects caused by antiemetics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Prospective observational study conducted in a tertiary-care hospital from February 2023 to May 2024 in patients starting chemotherapy or a new treatment line. CINV was evaluated using MASCC antiemetic tool, in acute (&lt;\u200924\u00a0h) and delayed phases (24\u2013120\u00a0h). Results were analyzed using <jats:italic>\u03c7<\/jats:italic>\n              <jats:sup>2<\/jats:sup> test or Fisher\u2019s exact test. The primary endpoint was complete response (CR) rate, defined as no CINV and no use of rescue medication. Univariate and multivariate logistic regressions were used to identify patient-related risk factors associated with non-CR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 176 completed questionnaires (CQ): 94 for males and 82 for females were collected. The proportion of males who remained emesis-free was superior to females in the acute phase (100% versus 92.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). Likewise, a higher proportion of males remained nausea-free in the acute (91.5% versus 79.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.021) and delayed phase (90.4% versus 79.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.037). In females, young age (&lt;\u200960\u00a0years) and previous nausea and vomiting during pregnancy may contribute to non-CR. A high proportion of patients reported adverse events like constipation and insomnia. Females suffered more constipation than males (52.4% versus 37.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.043).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Females experienced more CINV than males, with the consequences that entail. Antiemetic prophylaxis should be personalized, considering sex and age and not only the chemotherapy emetic potential.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09319-7","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T18:58:55Z","timestamp":1741633135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of chemotherapy-induced nausea and vomiting in low, moderate, and highly emetogenic schemes between sexes"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-670X","authenticated-orcid":false,"given":"Marta","family":"Albanell-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Carmen","family":"Rodr\u00edguez Mues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Figueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Altamirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-9102","authenticated-orcid":false,"given":"In\u00e9s","family":"Monge-Escart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8259-0811","authenticated-orcid":false,"given":"Gisela","family":"Riu-Viladoms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3060-4577","authenticated-orcid":false,"given":"Esther","family":"Carcelero San Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa Lourdes","family":"Corominas Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6898-0557","authenticated-orcid":false,"given":"Lydia","family":"Gaba Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"5","key":"9319_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, De Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting - incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503","journal-title":"Support Care Cancer"},{"issue":"8","key":"9319_CR2","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00520-018-4120-6","volume":"26","author":"S Puri","year":"2018","unstructured":"Puri S, Hyland KA, Weiss KC et al (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26(8):2911\u20132918","journal-title":"Support Care Cancer"},{"issue":"27","key":"9319_CR3","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472\u20134478","journal-title":"J Clin Oncol"},{"issue":"2","key":"9319_CR4","first-page":"CD007786","volume":"2","author":"RS Phillips","year":"2016","unstructured":"Phillips RS, Friend AJ, Gibson F et al (2016) Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2(2):CD007786","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"9319_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","volume":"20","author":"DL Hilarius","year":"2012","unstructured":"Hilarius DL, Kloeg PH, Van Der Wall E et al (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107\u2013117","journal-title":"Support Care Cancer"},{"issue":"10","key":"9319_CR6","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.clinthera.2020.08.007","volume":"42","author":"I Nasu","year":"2020","unstructured":"Nasu I, Shimano R, Kawazoe H et al (2020) Patient-related risk factors for nausea and vomiting with standard antiemetics in patients with cancer receiving carboplatin: a retrospective study. Clin Ther 42(10):1975\u20131982","journal-title":"Clin Ther"},{"issue":"6","key":"9319_CR7","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1007\/s00520-022-06956-0","volume":"30","author":"NS Badarudin","year":"2022","unstructured":"Badarudin NS, Mohamed Shah N, Mohd Kassim KNB et al (2022) A retrospective study on chemotherapy-induced nausea and vomiting in highly\/moderately emetogenic chemotherapy: incidence and prescribing practice. Support Care Cancer 30(6):5339\u20135349","journal-title":"Support Care Cancer"},{"issue":"1","key":"9319_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27(1):87\u201395","journal-title":"Support Care Cancer"},{"issue":"4","key":"9319_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/jcph.1338","volume":"59","author":"J Gilmore","year":"2019","unstructured":"Gilmore J, Bernareggi A (2019) Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol 59(4):472\u2013487","journal-title":"J Clin Pharmacol"},{"issue":"14","key":"9319_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367","journal-title":"N Engl J Med"},{"issue":"24","key":"9319_CR11","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797","journal-title":"J Clin Oncol"},{"key":"9319_CR12","first-page":"107815522311940","volume":"10","author":"M Albanell-Fern\u00e1ndez","year":"2023","unstructured":"Albanell-Fern\u00e1ndez M, P\u00e9rez S\u00e1nchez \u00c1, Monge-Escart\u00edn I et al (2023) Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy. J Oncol Pharm Pract 10:10781552231194076","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"9319_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.farma.2009.11.001","volume":"34","author":"MJ Huertas-Fern\u00e1ndez","year":"2010","unstructured":"Huertas-Fern\u00e1ndez MJ, Mart\u00ednez-Bautista MJ, S\u00e1nchez-Mart\u00ednez I et al (2010) An\u00e1lisis de la efectividad de un protocolo de antiemesis implantado en la Unidad de Oncolog\u00eda. Farm Hosp 34(3):125\u2013138","journal-title":"Farm Hosp"},{"issue":"4","key":"9319_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4103\/apjon.apjon-2120","volume":"8","author":"X Huang","year":"2021","unstructured":"Huang X, Li X, Li J et al (2021) Chemotherapy-induced nausea and vomiting in breast cancer patients: a multicenter prospective observational study. Asia Pac J Oncol Nurs 8(4):433\u2013437","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"1","key":"9319_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mdj078","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Aapro M, Ballatori E et al (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20\u201328","journal-title":"Ann Oncol"},{"issue":"6","key":"9319_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K et al (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104(6):711\u2013717","journal-title":"Cancer Sci"},{"issue":"14","key":"9319_CR17","first-page":"S259","volume":"23","author":"N Adel","year":"2017","unstructured":"Adel N (2017) Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care 23(14):S259\u2013S265","journal-title":"Am J Manag Care"},{"issue":"3","key":"9319_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/oncolo\/oyac240","volume":"28","author":"R Navari","year":"2023","unstructured":"Navari R, Binder G, Molasiotis A et al (2023) Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles. Oncologist 28(3):208\u2013213","journal-title":"Oncologist"},{"issue":"2","key":"9319_CR19","first-page":"1","volume":"30","author":"Y Baba","year":"2016","unstructured":"Baba Y, Baba H, Yamamoto S et al (2016) Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Dis Esophagus 30(2):1\u20137","journal-title":"Dis Esophagus"},{"issue":"12","key":"9319_CR20","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1007\/s00405-022-07505-5","volume":"279","author":"C Hu","year":"2022","unstructured":"Hu C, Yang W, Kong W et al (2022) Risk factors for Meniere disease: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 279(12):5485\u20135496","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"10","key":"9319_CR21","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/anae.13082","volume":"70","author":"T Hayase","year":"2015","unstructured":"Hayase T, Sugino S, Moriya H et al (2015) TACR1 gene polymorphism and sex differences in postoperative nausea and vomiting. Anaesthesia 70(10):1148\u20131159","journal-title":"Anaesthesia"},{"key":"9319_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3357\/AMHP.4243.2015","volume":"86","author":"F Koslucher","year":"2015","unstructured":"Koslucher F, Haaland EM, Malsch A et al (2015) Sex differences in the incidence of motion sickness induced by linear visual oscillation. Aerosp Med Hum Perform 86:787\u2013793","journal-title":"Aerosp Med Hum Perform"},{"key":"9319_CR23","unstructured":"World Health Organization (2024) Global cancer observatory. Int Agency Res Cancer. https:\/\/gco.iarc.fr\/overtime\/en\/dataviz\/bars?sexes=1_2&sort_by=value2. [Accessed on 6 June 2024]"},{"key":"9319_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"A Mosa","year":"2020","unstructured":"Mosa A, Hossain AM, Lavoie BJ et al (2020) Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol 11:329","journal-title":"Front Pharmacol"},{"issue":"9","key":"9319_CR25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1248\/bpb.b17-00318","volume":"40","author":"M Uchida","year":"2017","unstructured":"Uchida M, Mori Y, Nakamura T et al (2017) Comparison between antiemetic effects of palonosetron and granisetron on chemotherapy-induced nausea and vomiting in Japanese patients treated with R-CHOP. Biol Pharm Bull 40(9):1499\u20131505","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"9319_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","volume":"27","author":"D Tsuji","year":"2019","unstructured":"Tsuji D, Suzuki K, Kawasaki Y et al (2019) Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer 27(3):1139\u20131147","journal-title":"Support Care Cancer"},{"issue":"8","key":"9319_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","volume":"18","author":"Y Tsuji","year":"2017","unstructured":"Tsuji Y, Baba H, Takeda K et al (2017) Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother 18(8):753\u2013758","journal-title":"Expert Opin Pharmacother"},{"key":"9319_CR28","doi-asserted-by":"publisher","unstructured":"Binder G, Saunders W (2018) Chemotherapy-induced nausea and vomiting (CINV) - incidence by age and sex among patients receiving oxaliplatin. Value Health S14. https:\/\/doi.org\/10.1055\/s-0041-1729493","DOI":"10.1055\/s-0041-1729493"},{"issue":"2","key":"9319_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cac2.12397","volume":"43","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhao B, Chen G et al (2023) Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer Commun (Lond) 43(2):246\u2013256","journal-title":"Cancer Commun (Lond)"},{"issue":"18","key":"9319_CR30","doi-asserted-by":"publisher","first-page":"18745","DOI":"10.1002\/cam4.6494","volume":"12","author":"T Yokokawa","year":"2023","unstructured":"Yokokawa T, Suzuki K, Tsuji D et al (2023) Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: a retrospective observational study. Cancer Med 12(18):18745\u201318754","journal-title":"Cancer Med"},{"issue":"2","key":"9319_CR31","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2):102195","journal-title":"ESMO Open"},{"issue":"12","key":"9319_CR32","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.clinthera.2018.10.004","volume":"40","author":"H Kawazoe","year":"2018","unstructured":"Kawazoe H, Murakami A, Yamashita M et al (2018) Patient-related risk factors for nausea and vomiting with standard antiemetics in patients with breast cancer receiving anthracycline-based chemotherapy: a retrospective observational study. Clin Ther 40(12):2170\u20132179","journal-title":"Clin Ther"},{"issue":"6","key":"9319_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin\u2013cyclophosphamide-based chemotherapy. Support Care Cancer 19(6):807\u2013813","journal-title":"Support Care Cancer"},{"issue":"1","key":"9319_CR34","first-page":"14","volume":"11","author":"G Dranitsaris","year":"2012","unstructured":"Dranitsaris G, Bouganim N, Milano C et al (2012) Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. J Support Oncol 11(1):14\u201321","journal-title":"J Support Oncol"},{"issue":"6","key":"9319_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3747\/co.19.1074","volume":"19","author":"N Bouganim","year":"2012","unstructured":"Bouganim N, Dranitsaris G, Hopkins S et al (2012) Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol 19(6):414\u2013421","journal-title":"Curr Oncol"},{"issue":"2","key":"9319_CR36","doi-asserted-by":"publisher","first-page":"e2476","DOI":"10.1097\/MD.0000000000002476","volume":"95","author":"Z Hu","year":"2016","unstructured":"Hu Z, Liang W, Yang Y et al (2016) Personalized estimate of chemotherapy-induced nausea and vomiting. Medicine 95(2):e2476","journal-title":"Medicine"},{"issue":"8","key":"9319_CR37","doi-asserted-by":"publisher","first-page":"e2426076","DOI":"10.1001\/jamanetworkopen.2024.26076","volume":"7","author":"V Ostwal","year":"2024","unstructured":"Ostwal V, Ramaswamy A, Mandavkar S et al (2024) Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Netw Open 7(8):e2426076","journal-title":"JAMA Netw Open"},{"issue":"5","key":"9319_CR38","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00520-019-05280-4","volume":"28","author":"R Chow","year":"2020","unstructured":"Chow R, Valdez C, Chow N et al (2020) Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. Support Care Cancer 28(5):2095\u20132103","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09319-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T03:04:09Z","timestamp":1749611049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09319-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["9319"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09319-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki\u2019s ethical principles for medical research. Approval was granted by the Medical Ethical Committee of the Hospital Clinic of Barcelona (Reference number: HCB\/2023\/0014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}